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Background: Anti-PD-1-based therapies prolong survival in advanced melanoma, but disease progression
is common. This study evaluated treatment patterns and overall survival (OS) after anti-PD-1 progression.
Methods: Retrospective data from patients with advanced melanoma and progression on anti-PD-1
treatment between 2014 and 2019 were taken from Flatiron Health, which reflects largely community
practice. Treatment patterns and OS were analyzed for BRAF mutant (mt) and wild-type (wt) subgroups;
OS was also examined across all patients. Results: Progression following anti-PD-1 was recorded for 679
patients. Median OS ranged from 5.0 to 11.3 months. Of 275 BRAFmt and 374 BRAFwt patients, 113
(41.1%) and 228 (61.0%) received no subsequent therapy, respectively. However, 48.4% of BRAFmt and
57.8% of BRAFwt patients continued anti-PD-1 treatment beyond progression. Conclusion: This real-world
study underscores the need for effective treatments for advanced melanoma post-progression on anti-PD1 therapy.
First draft submitted: 17 March 2021; Accepted for publication: 4 January 2022; Published online:
7 February 2022
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Melanoma is the most lethal form of skin cancer, and incidence has risen rapidly over recent decades [1,2]. Advanced
melanoma is highly aggressive and associated with a poor prognosis. From 2010 to 2016, the Surveillance,
Epidemiology, and End Results Program estimated that 66.2% of patients whose initial diagnosis was stage III
melanoma, and just 27.3% of patients whose initial diagnosis was stage IV melanoma were expected to survive the
5-year mark [3].
Treatment for advanced melanoma has evolved considerably in recent years with the development of immunotherapy and targeted therapy. Checkpoint inhibition, a type of immunotherapy, has become a cornerstone of
the melanoma treatment armamentarium for oncologists. Examples of checkpoint inhibitors include anti-PD-1 and
CTLA-4 inhibitors. In clinical trials, these treatments have been found to be more effective than chemotherapy and
are associated with prolonged progression-free survival (PFS) and overall survival (OS) [3–5]. Additional treatment
options exist for patients with advanced melanoma who have a mutation in the BRAF V600 gene (approximately
50%) [6]; targeted BRAF/MEK inhibitors have been found to improve clinical outcomes in this population [7–9].
Despite the clinical success of anti-PD-1 immunotherapies, there is still a large proportion of patients that fails to
respond to these therapies initially (i.e., primary resistance) or respond but later relapse (i.e., acquired resistance) [10–
12]. Data from clinical trials indicate a response rate of approximately 33–50% with first-line, single-agent antiPD-1 therapy [13–16] and up to 60% for nivolumab plus ipilimumab [13,14,17]. Many patients thus need subsequent
treatment in the second line, but no standard of care currently exists. Recent studies have shown that treatment
with ipilimumab or retreatment with anti-PD-1 therapies in combination with ipilimumab are viable options for
patients who have progressed on prior anti-PD-1 treatment [18–20]. Patients with a BRAF V600 mutation (BRAFmt)
with disease progression on first-line anti-PD-1 therapies frequently receive BRAF + MEK inhibitor therapy [21,22].
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Few studies have examined OS after the point of disease progression on anti-PD-1 therapy, although a recent
retrospective study of patients with advanced melanoma found the median OS after disease progression on antiPD-1 therapy to be 6.8 months [23]. Another study [24] examined patients retreated with immunotherapy following
disease progression on initial anti-PD-1 therapy; OS at 1 year after the start of retreatment was 57% for patients
treated with ipilimumab plus anti-PD-1 therapy, compared with 38% for ipilimumab therapy alone.
It is important to understand the real-world treatments and outcomes of patients with advanced melanoma
who have experienced disease progression on anti-PD-1 therapy. Therefore, the aim of this study was to better
understand treatment patterns and OS estimates after disease progression on anti-PD-1 therapies, overall and in
the BRAFmt and BRAF wild-type (BRAFwt) populations.
Methods
Data Source

The Flatiron Heath database was used for this retrospective cohort study. Flatiron Health is a nationwide, longitudinal, demographically and geographically diverse database derived from deidentified electronic health record
(EHR) data. At the time of the analyses, the database contained data from more than 280 cancer clinics (∼800
sites of care) and more than 2.2 million US cancer patients [25]. Deidentified patient-level data include structured and unstructured data, curated via technology-enabled abstraction. Disease progression was identified from
records indicating that the treating clinician had concluded that there had been tumor growth or worsening of the
melanoma. A custom data extract was constructed, including patients with advanced melanoma. Patients had a
diagnosis of melanoma (International Classification of Diseases, 9th Revision [ICD] 172.x or ICD, 10th Revision
[ICD-10] C43x or D03x), pathologic stages III or IV at initial diagnosis or locoregional or distant recurrence
following diagnosis at an earlier stage of disease and two clinic encounters in the Flatiron database. Patients with
noncutaneous types of melanoma (ocular, subungual, mucosal, palmar and plantar) were excluded, as were those
with a diagnosis of a primary cancer type other than melanoma, basal or squamous cell skin cancer or carcinoma
in situ of the prostate, cervix or breast before the date of disease progression during anti-PD-1 therapy.
Study data complied with US patient confidentiality requirements. Because the study used only existing deidentified patient records, Institutional Review Board approval and patient informed consent were not required.
Study population
The study cohort included patients aged ≥18 years diagnosed with advanced melanoma and who received antiPD-1 treatment at any line of therapy (LOT). Included patients experienced disease progression on treatment
with anti-PD-1 therapy, as a single agent or in combination (most often with ipilimumab), or died without
having a record of disease progression while on treatment. Patients were excluded for having been treated with an
investigational agent for cancer during or before the first anti-PD-1 LOT. Included patients met all inclusion and
exclusion criteria from 1 September 2014 to 30 November 2019.
The study index date was defined as the first recorded date of disease progression (excluding pseudo-progression
or mixed disease progression) at least 14 days after the start of the first anti-PD-1 LOT and before the start of any
subsequent LOTs. Patients were followed until death or their last visit before data cutoff (31 May 2020).
In patients who died without a record of disease progression while on anti-PD-1 therapy, an index date based on
disease progression could not be determined. Therefore, these patients were removed from the main analyses and
their baseline characteristics were summarized separately.
Study variables
Baseline demographic and clinical characteristics – including tumor status, number and type of prior LOTs, disease
characteristics, BRAF status, time between the start of the first anti-PD-1 LOT and the disease progression date, as
well as evidence of disease progression (radiographic, pathologic or clinical assessment) – were extracted from the
EHR.
Outcomes
Treatment pattern data were extracted following disease progression on anti-PD-1 therapy, including subsequent
treatment type and continued time on the anti-PD-1 therapy following the disease progression event (i.e., treatment
beyond disease progression). The OS was calculated from the date of anti-PD-1 disease progression to the date of
death. In patients with no record of death, OS was censored at the last visit in the study period.
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Statistical analysis
Study measures, including baseline characteristics and treatment patterns, were summarized with descriptive
statistics. Mean, standard deviation (SD), median and range were reported for continuous measures. Categorical
measures were summarized using frequencies and percentages. The median OS with a 95% CI was estimated using
Kaplan–Meier methods. Analyses were conducted separately for patients with and without BRAF mutations due to
expected differences in treatments and outcomes between these two patient groups. In the BRAFmt group, analyses
were also run in a subgroup of patients who had treatment with BRAF therapy (with or without an MEK inhibitor)
before or during their index LOT (the first LOT containing an anti-PD-1 agent). Sensitivity analyses for OS, adding
the patients who died without a record of disease progression while on anti-PD-1 therapy, were performed using
a disease progression date imputed as the median time from anti-PD-1 initiation to disease progression among
patients with the same BRAF status who had a record of disease progression. The imputed disease progression
date was set to the death date for patients who died before the median time to disease progression. An additional
sensitivity analysis examined OS separately for patients with and without further treatment with the anti-PD-1
beyond progression.
Results
Patient attrition

A total of 6256 patients with advanced melanoma were identified, of whom 2751 had a treatment regimen at any
LOT containing an anti-PD-1 therapy. Of those patients, 1373 had a record in the database of progression or
death during the cohort identification period. After applying the remaining inclusion and exclusion criteria, there
were 1035 patients; 356 (34.4%) died without a record of disease progression, leaving 679 patients for the primary
analyses (Figure 1). Of these, 275 and 374 had BRAFmt and BRAFwt melanoma, respectively, with 30 patients
having unknown BRAF status.
Overall population
Baseline demographic & clinical characteristics

In the overall cohort of 679 patients, the median age was 68 years; 68.0% were male (Table 1). The majority (84.8%)
of patients were white, and most (90.0%) were treated in a community practice. At initial melanoma diagnosis,
most of these patients with advanced melanoma had stage IV disease (33.9%), followed by stage II (19.4%), stage
III (19.3%) and stage I (9.0%). One patient (0.1%) had stage 0 disease, and 18.3% of patients had an unknown
stage. Diagnosis codes for brain metastases were present in 20.3% of patients prior to their disease progression date,
although this may have been under-reported in the EHR. Most patients had an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0–1 (27.0% at ECOG 0; 29.9% at ECOG 1) at or within 6 months
before the index disease progression date, and 17.8% had an ECOG PS of 2 or higher; ECOG PS was unknown
for 25.3% of patients (Table 1).
Overall survival

Median OS from the index disease progression date was 11.3 months (95% CI: 9.9–12.5) in the primary analysis,
which includes only those 679 patients with a recorded disease progression date (Figure 2). When adding the 356
patients who died before a record of disease progression to the primary cohort, the median OS was reduced from
11.3 to 5.0 months (95% CI: 4.2–6.2).
BRAFmt cohort
Baseline demographic, clinical & treatment characteristics

Among the 275 patients with BRAFmt, the median age was 65 years (Table 1). The most common disease stages
at initial melanoma diagnosis were stage IV (30.5%) and stage III (21.8%), with 10.5 and 17.1% at stages I and
II, respectively, and 20.0% with unknown stage. Diagnosis codes for brain metastases were present in 25.8% of
patients before their disease progression date (Table 1).
Anti-PD-1 treatment occurred during the first LOT for 74.9% of patients. The most common treatment received
before the index LOT was BRAF therapy with or without a MEK inhibitor (21.8%) or anti-CTLA-4 monotherapy
(3.6%; Figure 3). Patients received nivolumab and ipilimumab combination therapy (33.1%), pembrolizumab
monotherapy (30.5%) or nivolumab monotherapy for their index LOT (26.5%; Figure 3). The median time from
start of the index LOT until the disease progression date was 2.5 months.
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Table 1. Baseline demographic and clinical characteristics for patients with advanced melanoma by BRAF status.
Baseline

Overall (n = 679)

BRAFmt (n = 275)

BRAFwt (n = 374)

68 (58–77)

65 (52–74)

71 (61–79)

Male

462 (68.0%)

182 (66.2%)

261 (69.8%)

Female

217 (32.0%)

93 (33.8%)

113 (30.2%)

Demographic characteristic
Age (years) at index date
Median (IQR)
Sex

Race
White

576 (84.8%)

243 (88.4%)

310 (82.9%)

Black or African American

6 (0.9%)

2 (0.7%)

4 (1.1%)

Asian

1 (0.1%)

0 (0.0%)

1 (0.3%)

Other

55 (8.1%)

13 (4.7%)

39 (10.4%)

Unknown

41 (6.0%)

17 (6.2%)

20 (5.3%)

Practice type
Academic

68 (10.0%)

39 (14.2%)

28 (7.5%)

Community

611 (90.0%)

236 (85.8%)

346 (92.5%)

Index year
2015

36 (5.3%)

14 (5.1%)

22 (5.9%)

2016

107 (15.8%)

41 (14.9%)

58 (15.5%)

2017

162 (23.9%)

69 (25.1%)

90 (24.1%)

2018

220 (32.4%)

85 (30.9%)

125 (33.4%)

2019

154 (22.7%)

66 (24.0%)

79 (21.1%)

20.4 (7.6–45.7)

21.7 (8.2–53.1)

20.2 (7.5–44.8)

7.8 (3.9–16.1)

7.9 (3.9–15.3)

7.8 (3.7–16.8)

0

1 (0.1%)

0 (0.0%)

1 (0.3%)

I

61 (9.0%)

29 (10.5%)

30 (8.0%)

II

132 (19.4%)

47 (17.1%)

76 (20.3%)

III

131 (19.3%)

60 (21.8%)

64 (17.1%)

IV

230 (33.9%)

84 (30.5%)

137 (36.6%)

Unknown

124 (18.3%)

55 (20.0%)

66 (17.6%)

Clinical characteristic
Time (months) from diagnosis to index date
– From initial melanoma diagnosis
Median (IQR)
– From first diagnosis of advanced melanoma
Median (IQR)
– Stage at initial melanoma diagnosis

– Presence of brain metastases on or before index

date†

Yes

138 (20.3%)

71 (25.8%)

65 (17.4%)

No/unknown

541 (79.7%)

204 (74.2%)

309 (82.6%)

100 (26.7%)

– ECOG performance status; measurement on the index date or closest within 6 months earlier
0

183 (27.0%)

73 (26.5%)

1

203 (29.9%)

81 (29.5%)

115 (30.7%)

2

96 (14.1%)

40 (14.5%)

52 (13.9%)

3

19 (2.8%)

5 (1.8%)

10 (2.7%)

4

6 (0.9%)

2 (0.7%)

3 (0.8%)

Unknown

172 (25.3%)

74 (26.9%)

94 (25.1%)

Cell entries show n (%), unless otherwise specified. Patients with unknown BRAF status are excluded from the BRAF-stratified columns.
† Presence of brain metastases may be under-reported.
ECOG: Eastern Cooperative Oncology Group; IQR: Interquartile range; mt: Mutation; wt: Wild-type.
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Total patients identified in Flatiron data with advanced melanoma
n = 10,039 (100.0%)

Patients diagnosed with advanced melanoma (stage lll or lV, unresectable
melanoma, excluding nonskin types [ocular, subungual, mucosal, palmar,
and plantar]) from 1 September 2014 to 16 November 2019
n = 6256 (62.3%)

Excluded
n = 3783

Receipt of at least one LOT containing an anti-PD-1 agent
(i.e., nivolumab or pembrolizumab) starting on
or after the first diagnosis of advanced melanoma
n = 2751 (27.4%)

Excluded
n = 3505

Between 15 September 2014 and 30 November 2019, either at least one
instance of progression occurring at least 14 days after the start of the first
anti-PD-1 LOT and prior to the start of any subsequent lines, if any, OR
death any time after start of first anti-PD-1 LOT without a progression
event (index date) n = 1373 (13.7%)

Excluded
n = 1378

Administration dates recorded during the index anti-PD-1 LOT
(first LOT containing an anti-PD-1 agent after a diagnosis of advanced
melanoma) for the specific anti-PD-1 therapy in that LOT
n = 1301 (13.0%)

Excluded
n = 72

No diagnosis of a primary cancer type other than melanoma,
basal or squamous cell skin cancer or carcinoma
in situ of the prostate, cervix or breast
n = 1058 (10.5%)

Excluded
n = 243

Aged 18 years or older at index date
n = 1058 (10.5%)

Excluded
n=0

No use of an investigational agent for cancer during
the index line on or prior to index date
n = 1035 (10.3%)

Excluded
n = 23

Exclude patients who died anytime after the start of the index
anti-PD-1 LOT with no evidence of progression
n = 679 (6.8%)

Excluded
n = 356

BRAFmt
n = 275 (40.5%)

BRAFwt
n = 374 (55.1%)

Unknown BRAF status
n = 30 (4.4%)

Figure 1. Study attrition for the anti-PD-1-treated advanced melanoma cohort. Index date is defined as the first
date of progression (not including pseudo progression or mixed progression) occuring at least 14 days after the first
line of therapy containing an anti-PD-1 and prior to any aubsequent lines of therapy.
LOT: Line of therapy; NA: Not available; Mt: Mutation; Wt: Wild-type.

First subsequent therapy treatment patterns

More than one-third of patients (41.1%) had no subsequent treatment (i.e., no new LOT initiated) after their
index LOT (Figure 3). In those patients with a subsequent treatment, the most common therapy received was
BRAF-targeted therapy, alone or in combination with an MEK inhibitor (36.7%). Of those without a subsequent
treatment, just over one-third (38.9%) had received BRAF therapy as part of or before their index LOT.

future science group

www.futuremedicine.com

1347

Research Article

Nordstrom, Hamilton, Collins et al.

Product-limit survival estimate
with number of subjects at risk
1.0
Censored
0.8
Survival probability

Median (95% Cl) OS (months): 11.3 (9.9, 12.5)
0.6

0.4

0.2

0.0
At risk

679

303

0

10

138

57

19

30
40
20
Overall survival from index, months

6

0

50

60

Figure 2. Overall survival from the index date, total cohort. The index date was the date of disease progression on
the index anti-PD-1 line of therapy.
OS: Overall survival.
BRAFmt (n = 275)

BRAFwt (n = 374)

Baseline treatment
n (%)

First subsequent therapy
after progression
n (%)

Baseline treatment
n (%)

First subsequent therapy
after progression
n (%)

No treatment
206 (74.9%)

No treatment
113 (41.1%)

No treatment
343 (91.7%)

No treatment
228 (61.0%)

BRAF ± MEK
60 (21.8%)

BRAF ± MEK
101 (36.7%)

BRAF ± MEK
0 (0.0%)

BRAF ± MEK
0 (0.0%)

Anti-CTLA-4 alone
10 (3.6%)

BRAF ± MEK + IO
13 (4.7%)

Anti-CTLA-4 alone
27 (7.2%)

BRAF ± MEK + IO
0 (0.0%)

Chemotherapy alone
2 (0.7%)

MEK monotherapy
0 (0.0%)

Chemotherapy alone
3 (0.8%)

MEK monotherapy
2 (0.5%)

BRAF ± MEK + IO
1 (0.4%)

MEK + IO
0 (0.0%)

Anti-angiogenic + IO
1 (0.3%)

MEK + IO
1 (0.3%)

MEK monotherapy
1 (0.4%)

Anti-PD-1 switch
4 (1.5%)

Other
2 (0.5%)

Anti-PD-1 switch
32 (8.6%)
Anti-CTLA-4 alone
19 (5.1%)

Anti-CTLA-4 alone
7 (2.5%)
Anti-CTLA-4 + anti-PD-1
17 (6.2%)

Index anti-PD-1 LOT
n (%)

Anti-CTLA-4 + anti-PD-1
40 (10.7%)

Chemotherapy alone
8 (2.9%)

Nivolumab monotherapy
138 (36.9%)

Chemotherapy alone
24 (6.4%)

Chemotherapy + IO
0 (0.0%)

Pembrolizumab monotheray
116 (31.0%)

Chemotherapy + IO
4 (1.1%)

Clinical study drug, alone/combo
9 (3.3%)

Nivolumab + ipilimumab
114 (30.5%)

Clinical study drug, alone/combo
13 (3.5%)

Anti-CTLA-4 + anti-PD-1
0 (0.0%)

Anti-angiogenic alone
0 (0.0%)

Anti-CTLA-4 + anti-PD-1
4 (1.1%)

Anti-angiogenic alone
3 (0.8%)

BRAF ± MEK + IO
26 (9.5%)

Anti-angiogenic + chemotherapy
0 (0.0%)

BRAF ± MEK + IO
0 (0.0%)

Anti-angiogenic + chemo
1 (0.3%)

Other
0 (0.0%)

Other
3 (1.1%)

Other
1 (0.3%)

Other
7 (1.9%)

Index anti-PD-1 LOT
n (%)
Nivolumab monotherapy
73 (26.5%)
Pembrolizumab monotherapy
84 (30.5%)
Nivolumab + ipilimumab
91 (33.1%)

Figure 3. Treatment patterns by BRAF status.
IO: Immunotherapy; LOT: Line of therapy; mt: Mutation; wt: Wild-type.
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Table 2. Follow-up duration and further treatment with index anti-PD-1 after index disease progression event.
BRAFmt

BRAFwt

Those with a subsequent
therapy

Those without a subsequent
therapy

Those with a subsequent
therapy

Those without a subsequent
therapy

n

162

113

146

228

Median (IQR)

10.9 (5.7–19.0)

3.9 (1.0–16.5)

9.5 (4.7–17.7)

6.5 (1.8–16.8)

Follow-up duration (months)

Time (months) from index date to discontinuation of index anti-PD-1 treatment for patients with at least one administration of index anti-PD-1 after progression
n (%) with at least one
administration
Median (IQR)

66 (40.7%)

67 (59.3%)

72 (49.3%)

144 (63.2%)

1.3 (0.7–6.0)

8.8 (1.3–17.1)

2.3 (0.6–4.3)

6.2 (1.4–15.6)

Patients with unknown BRAF status are excluded from the BRAF-stratified columns.
IQR: Interquartile range; mt: Mutation; wt: Wild-type.

Product-limit survival estimate for BRAF mutation
status = BRAFmt with number of subjects at risk
1.0

Censored

0.8
Median (95% CI) OS (months): 12.4 (10.6, 15.7)

0.6
0.4
0.2

0.0
At risk 275
0

134

59

27

8

20
40
10
30
Overall survival from index, months

3
50

Survival probability

Survival probability

1.0

Product-limit survival estimate for BRAF mutation
status = BRAFwt with number of subjects at risk

Censored

0.8
Median (95% CI) OS (months): 10.1 (8.5,12.4)

0.6
0.4
0.2

0.0
At risk 374
0

159

75

29

11

3

0

20
40
50
10
30
Overall survival from index, months

60

Figure 4. Overall survival from the index date, by BRAF status. The index date was the date of disease progression
on the index anti-PD-1 line of therapy.
mt: Mutation; OS: Overall survival; wt: Wild-type.

After the index disease progression event recorded in the database, further treatment with the index anti-PD-1
(i.e., treatment beyond disease progression) occurred in 48.4% of patients. Among patients who later initiated a new
LOT of any type, before initiating the subsequent therapy, 40.7% continued their anti-PD-1 treatment following
disease progression for a median of 1.3 months (Table 2). Among patients who did not go on to receive a subsequent
therapy, 59.3% continued their anti-PD-1 treatment after disease progression for a median of 8.8 months.
Overall survival

The median OS from the index disease progression date was 12.4 months (95% CI: 10.6–15.7) in the primary
analysis, which includes only those 275 patients with an identified disease progression date (Figure 4).
Subgroup analyses in patients with prior BRAF treatment

Analyses were also conducted on the subgroup of patients who received BRAF targeted treatment during or before
their index anti-PD-1 LOT; however, due to the small sample size (n = 78), results should be interpreted with
caution. After discontinuing their index LOT, 43.6% had a subsequent treatment (Supplementary Table 1). The
median OS after the disease progression event during the first anti-PD-1 line among these patients was only
5.4 months (Supplementary Figure 1).
Sensitivity analysis for OS in patients who died without a record of disease progression

An index disease progression date was imputed for 114 patients with BRAFmt where an index date could not be
established because death occurred without a record of disease progression. The median age of these patients was
65.7 years (Supplementary Table 2), and 34.2% had a recorded ECOG score of >1 (Supplementary Table 3). For
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more than half of patients (57.0%), the index anti-PD-1 LOT was their first LOT, and 35.1% of patients had one
prior LOT. The most common therapies received in prior lines were BRAF therapy, alone or in combination with
an MEK inhibitor (39.5%) and anti-CTLA-4 alone (4.4%; Supplementary Table 4).
For these 114 patients with an imputed date of disease progression, 72 died before or on the median time to
disease progression date, and therefore, by definition, had a survival time of 0 days. For the remaining 42 patients,
survival time was also limited, with a median time of 2.4 months from imputed disease progression date to death.
When adding the patients with an imputed index disease progression date to the primary cohort, the median OS
was reduced from 12.4 to 5.7 months (95% CI: 3.9–8.1).
Sensitivity analysis for patients with further treatment with the anti-PD-1 beyond progression

Median OS for patients who received at least one dose of their index anti-PD-1 after their progression event
was 24.6 (95% CI: 16.5–not available) months and was 8.0 (95% CI: 5.3–10.7) months for those whose index
anti-PD-1 therapy ended on or before the progression date (Supplementary Table 5).
BRAFwt cohort
Baseline demographic & clinical & treatment characteristics

The BRAFwt cohort included 374 patients (Figure 1). The median age was 71 years. Stage at initial diagnosis was
recorded for 82.4% of patients, with 8.0% stage I, 20.3% stage II, 17.1% stage III, 36.6% stage IV and 0.3% (one
patient) with stage 0. Brain metastases were recorded in 17.4% of patients before the date of disease progression
(Table 1).
The index LOT was the first LOT for 91.7% of patients. Before the index LOT, anti-CTLA-4 monotherapy was
the most common treatment received (7.2%; Figure 3). For their index LOT, approximately one-third of patients
received nivolumab monotherapy (36.9%), pembrolizumab monotherapy (31.0%) or nivolumab plus ipilimumab
combination therapy (30.5%; Figure 3). The median time from start of the index LOT until the disease progression
date was 3.0 months.
First subsequent therapy treatment patterns

After their index LOT, more than half of the patients with BRAFwt (61.0%) received no subsequent therapy.
Anti-CTLA-4 plus anti-PD-1 (10.7%) or an anti-PD-1 switch (8.6%; from the initial to an alternative anti-PD-1)
were the most common treatments for those patients who did receive a subsequent therapy. After the index disease
progression event, 57.8% of patients received further treatment with the index anti-PD-1. Among patients who
later received a subsequent therapy, 49.3% continued their anti-PD-1 treatment following the record of disease
progression, for a median of 2.3 months (Table 2). However, among patients who did not later receive a subsequent
therapy, 63.2% continued their anti-PD-1 treatment for a median of 6.2 months following disease progression.
Overall survival

For those with a recorded disease progression date (n = 374), the median OS from the index disease progression
date was 10.1 months (95% CI: 8.5–12.4; Figure 4).
Sensitivity analysis for OS in patients who died without a record of disease progression

In the sensitivity analysis, an index disease progression date was imputed for the 194 patients who did not have a
record of disease progression. The median age of these patients was 76 years (Supplementary Table 2), and ECOG
scores were 2 or higher for 37.1% of patients (Supplementary Table 3). The anti-PD-1 index line was the first LOT
for nearly all patients (95.4%), with only 4.1% having had one prior line. The most common treatment received
in prior lines was anti-CTLA-4 alone (4.6%; Supplementary Table 4).
Of the 194 patients whose date of disease progression was imputed, 107 died on or before this date and had
a survival time of 0 days. The remaining 87 patients had a median survival time of 4.6 months from imputed
disease progression date to death. Median OS for the full cohort plus the patients with an imputed index disease
progression date was 5.2 months (95% CI: 4.4–6.8), reduced from 10.1 months in the primary cohort.
Sensitivity analysis for patients with further treatment with the anti-PD-1 beyond progression

For patients with BRAFwt who received at least one dose of their index anti-PD-1 after progression, median OS
was 13.5 (95% CI: 11.1–18.0) months; patients without further treatment with their index anti-PD-1 therapy
post-progression had a median OS of 5.8 (95% CI: 3.8–7.9) months (Supplementary Table 5).
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Discussion
This retrospective cohort study using real-world data from Flatiron Health provides information on the treatment
patterns and OS of patients with advanced melanoma following disease progression on anti-PD-1 treatment. Our
findings show that 53.5% of all patients – more than 40% of BRAFmt and more than 60% of BRAFwt – did not
initiate another treatment regimen within the Flatiron system after a record of disease progression on anti-PD-1.
Compared with this finding, previous studies found even higher proportions of patients not receiving a second
LOT following first-line anti-PD-1-containing treatment, although documented disease progression on the first
LOT was not required and patients may not have received further treatment due to long-term response [21,26].
A Danish retrospective cohort study by Bastholt et al. that examined subsequent treatment patterns following
discontinuation of first-line pembrolizumab in patients with metastatic melanoma found that 70% of patients did
not initiate another treatment in the second line [26]. Moser et al., who conducted a retrospective study using data
from Flatiron Health to assess treatment patterns and survival among patients with BRAFmt advanced melanoma,
found that 72.2% of patients treated with nivolumab plus ipilimumab and 59.3% of those receiving anti-PD-1
monotherapy in the first line received no subsequent therapy. Median OS for patients treated with first-line antiPD-1 therapy was 39.5 months; however, because patients did not necessarily progress on the anti-PD-1 therapy,
the result is not directly comparable to that of the current study [21].
In the current study, patients with BRAFmt melanoma most commonly received BRAF inhibitor therapy with
or without a MEK inhibitor (34%) in their subsequent treatment, whereas anti-CTLA-4 plus anti-PD-1 (9%)
and anti-PD-1 switch (9%) were the most common subsequent therapies for patients with BRAFwt. The BRAFmt
treatment patterns are generally consistent with data presented in previous studies. Moser et al., who produced
another Flatiron study of patients with BRAFmt advanced melanoma, found that BRAF/MEK inhibitors were
the most frequently observed subsequent therapy for patients who received a second line after first-line anti-PD-1
treatment (66%) [21]. Schilling et al., who assessed survival among patients with BRAFmt advanced melanoma
stratified by first-line therapy, found that among the patients initiating first-line therapy with anti-PD-1, the most
common subsequent therapy was BRAF therapy plus MEK inhibitors (30.6% of those receiving a subsequent
systemic therapy) [22]. Previous studies examining subsequent treatment patterns without stratifying patients by
BRAF status have found that retreatment with anti-PD-1 therapy, ipilimumab or a combination of both are often
used as subsequent therapies for patients who have failed on prior anti-PD-1 treatment [18–20,23,26]. This is consistent
with the most common subsequent treatments for the BRAFwt population in the current study.
In the current study, the index anti-PD-1 was the first LOT for approximately 72% of patients with BRAFmt
melanoma and approximately 90% of patients with BRAFwt melanoma. With the availability of targeted therapies,
patients with BRAFmt have more treatment options than patients with BRAFwt. A large proportion (61.0%)
of patients with BRAFwt had no record of a subsequent therapy, and many of these patients (57.8%) had at
least one administration of their index anti-PD-1 following the disease progression event. Of those who did
receive a subsequent therapy, 9% had an anti-PD-1 switch, which may reflect insufficient treatment options,
especially for BRAFwt melanoma. Fortunately, newer treatment options for advanced melanoma after progression
on anti-PD-1 therapy are in development, including new immunotherapies, such as LAG-3-targeted monoclonal
antibodies [27], TIM-3 [28], GITR antibodies [29] and TLR9 agonists [30,31]. Oncolytic viruses, such as talimogene
laherparepvec (T-VEC) [32,33], in combination with other therapies are also under investigation [34]. Recently, the
phase III DREAMseq study found that in patients with treatment-naive BRAFmt, nivolumab plus ipilimumab
given before dabrafenib plus trametinib was associated with longer OS (2-year rate of 72 vs 52% in patients who
received the opposite sequence). These findings suggest that starting the treatment sequence for BRAFmt melanoma
with immunotherapy rather than targeted therapy may extend OS for many patients [35,36].
After disease progression on anti-PD-1, median survival was approximately 12 months for patients with BRAFmt
and 10 months for those with BRAFwt in the current study. However, a sensitivity analysis including the >30% of
patients who died without a record of disease progression reduced those estimates to nearly 6 months for those with
BRAFmt and 5 months for those with BRAFwt. A recent retrospective study by Patrinely et al. examining clinical
outcomes of patients with advanced melanoma after disease progression on anti-PD-1 therapy found median OS
to be 6.8 months [23]. However, the investigators included a systematic assessment of disease progression using
Response Evaluation Criteria in Solid Tumors (RECIST) criteria rather than evaluating clinical notes retrospectively
indicating disease progression, which may have resulted in an initial cohort more similar to the current study’s
sensitivity analysis that includes patients who died without a record of disease progression. Although OS post-disease
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progression in the primary cohort of the current study was close to 1 year, the inclusion of patients who died without
a record of disease progression produces far less optimistic results. Death of patients before disease progression is
captured does occur in clinical practice, in part due to incomplete documentation of disease progression in the
real-world setting. In other cases, the death may have occurred too quickly between visits so that disease progression
was never observed in the clinical practice. Some of the deaths may have been unrelated to disease progression,
where disease progression never occurred, although this is less likely in this population.
The primary analysis of this study might be more reflective of the experience of patients who may be eligible for
further treatment, whereas the sensitivity analysis may capture patients who exhibit primary resistance to anti-PD-1
therapies and die without having the opportunity to receive further treatment. Patients who died without a record
of disease progression were slightly older on average than the primary cohort, more likely to have been diagnosed
at stage IV and more likely to have an ECOG score >1. The sensitivity analysis may better demonstrate the reality
of poor survival and unmet need in those patients who experience disease progression on anti-PD-1 therapies [10]
with few remaining effective treatment options available to them. Overall, these findings highlight the need for
more effective treatments for advanced melanoma.
This analysis of real-world patients provides insights into the treatment patterns and survival of patients with
advanced melanoma who progressed on anti-PD-1 therapy treated in community practices. Unlike in clinical
trials, a benefit of this study is that there were less stringent inclusion criteria. In addition, post-disease-progression
survival has rarely been investigated previously; therefore, this study can serve as a benchmark for future research.
However, it should be noted that disease progression as measured in medical records may capture the real
clinical experience of trying to determine whether disease progression actually occurred, but disease progression
is not systematically assessed per protocol and may be erroneous in both fact and date of disease progression.
The frequent occurrence of continuing treatment with the anti-PD-1 therapy beyond progression suggests that
physicians likely saw some ongoing benefit to the treatment despite the apparent evidence of progression, again
highlighting that this real-world progression is substantially different from progression examined in clinical trials.
The longer OS for patients with treatment beyond progression relative to those without substantiates this notion.
Further limitations of this analysis include the lack of information on reasons for treatment decisions, missing
data on any care that occurred outside of the oncology clinic 1 and poor recording of comorbidities that were not
treated by the oncologist. Patients who sought care in a different oncology clinic or academic center, potentially
due to participation in a clinical trial, may have received further treatment that does not appear in the database;
thus, the proportion of patients receiving no subsequent therapy may be overestimated. The use of an ICD-10
code to identify brain metastases identified some patients but was likely under-recorded; care should be taken when
interpreting these numbers because the absence of the code does not necessarily mean that brain metastases were
not present. The majority of Flatiron’s data comes from community practice types (90% for the current study). It
should be noted that treatment pathways are defined slightly differently in academic versus community centers.
The heterogeneity of available treatment options during the cohort selection period, which extends back to 2014,
should also be noted as a possible weakness of the study because advances in the treatment of this patient population
have been made in recent years.
Conclusion
This real-world retrospective analysis of patients with advanced melanoma treated in the USA revealed that more
than 40% of patients with BRAFmt and 60% of patients with BRAFwt did not initiate a new treatment regimen
after disease progression on anti-PD-1 therapies. The median OS after disease progression on anti-PD-1 was 12.4
and 10.1 months for patients with BRAFmt and BRAFwt, respectively. This may be an overestimate because it
excluded patients who died before a clinical record of disease progression was captured in the data source; when
these patients are included with those from the primary cohort, median OS is reduced to 5.7 and 5.2 months for
patients with BRAFmt and BRAFwt, respectively. These results highlight the lack of treatment options for patients
with advanced melanoma who progress on anti-PD-1-based therapy.
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Summary points
• Real-world treatment patterns and outcomes after progression on anti-PD-1-based therapies for melanoma are
unknown.
• This retrospective, observational study used the Flatiron oncology electronic medical record database to assess
the treatment patterns and overall survival (OS) of patients with advanced melanoma following progression on
anti-PD-1 treatment.
• Median OS after progression was 11.3 months (95% CI: 9.9–12.5) overall, 12.4 months (95% CI: 10.6–15.7) for
patients with a BRAF mutation (BRAFmt) and 10.1 months (95% CI: 8.5–12.4) for patients with BRAF wild-type
(BRAFwt).
• For patients with BRAFmt, the most common subsequent therapy was BRAF-targeted therapy, alone or in
combination with a mitogen-activated protein kinase inhibitor (36.7%), but 41.1% of patients had no record of a
subsequent treatment.
• A new anti-PD-1-based regimen was the most common subsequent treatment for BRAFwt (19.3%), but 61.0%
had no record of a subsequent therapy.
• The high proportion of patients receiving no further treatment after progression on anti-PD-1 therapy (other
than potentially through a clinical trial), paired with relatively short survival durations, highlight the need for
additional treatment options for advanced melanoma.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/
suppl/10.2217/fon-2021-0340
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